Effect of Extracorporeal Membrane Oxygenation on the New Vancomycin Dosing Regimen in Critically III Patients Receiving Continuous Venovenous Hemofiltration

被引:9
|
作者
Yang, Chi-Ju [1 ]
Wu, Chia-Wei [1 ]
Wu, Chien-Chih [1 ,2 ]
机构
[1] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pharm, Coll Med, 7 Chung Shan S Rd, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
关键词
vancomycin; continuous venovenous hemofiltration (CVVH); extracorporeal membrane oxygenation (ECMO); critical care; RENAL REPLACEMENT THERAPY; ILL PATIENTS; POPULATION PHARMACOKINETICS; TROUGH CONCENTRATIONS; HEMODIALYSIS; CLEARANCE; RECOMMENDATIONS; INFECTION; ADEQUATE; FAILURE;
D O I
10.1097/FTD.0000000000000495
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The optimal dosing regimen of vancomycin for critically ill patients receiving continuous venovenous hemofiltration (CVVH) remains controversial, not to mention those with concurrent use of extracorporeal membrane oxygenation (ECMO). We aimed to determine if a new dosing regimen can achieve the target vancomycin trough concentration (C-trough) of 10-20 mcg/mL in patients receiving CVVH with or without ECMO. Methods: We conducted a retrospective study by enrolling patients who received vancomycin while undergoing CVVH. The vancomycin dosing regimen was 15-20 mg/kg as the loading dose and 7.5 mg/kg every 12 hours as the maintenance doses. Serum concentration was determined after at least 4 doses of vancomycin were given. Results: A total of 38 patients were enrolled, of which 21 were also on ECMO. The ultrafiltration rate of CVVH was 30.6 +/- 5.5 mL.kg(-1).h(-1) with the C-trough of 14.7 +/- 3.5 mcg/mL. C-trough was within the target range in 82% of patients. All CVVH-only patients achieved the target concentration, whereas only 76.2% of those with concurrent ECMO did (P = 0.031). Conclusions: All patients receiving CVVH achieved the target C-trough with this new dosing regimen, but those with concurrent ECMO did not. C-trough must be more closely monitored in patients using ECMO simultaneously.
引用
收藏
页码:310 / 314
页数:5
相关论文
共 50 条
  • [31] Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing
    Bouman, Catherine S. C.
    Van Kan, Hendrikus J. M.
    Koopmans, Richard P.
    Korevaar, JohannaC.
    Schultz, Marcus J.
    Vroom, Margreeth B.
    INTENSIVE CARE MEDICINE, 2006, 32 (12) : 2013 - 2019
  • [32] Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing
    Catherine S. C. Bouman
    Hendrikus J. M. van Kan
    Richard P. Koopmans
    Johanna C. Korevaar
    Marcus J. Schultz
    Margreeth B. Vroom
    Intensive Care Medicine, 2006, 32 : 2013 - 2019
  • [33] Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis
    Yu, Zhenwei
    Liu, Jieqiong
    Yu, Haitao
    Zhou, Ling
    Zhu, Jianping
    Liang, Gang
    Yang, Yi
    Zheng, Ying
    Han, Yun
    Xu, Junjun
    Han, Gang
    Yu, Lingyan
    Zhao, Yuhua
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [34] Continuous renal replacement therapy in patients receiving extracorporeal membrane oxygenation therapy
    Raja, Meera
    Leal, Ricardo
    Doyle, James
    JOURNAL OF THE INTENSIVE CARE SOCIETY, 2023, 24 (02) : 227 - 229
  • [35] Predilution versus Postdilution Continuous Venovenous Hemofiltration: No Effect on Filter Life and Azotemic Control in Critically Ill Patients on Heparin
    Nurmohamed, Shaikh A.
    Jallah, Borefore P.
    Vervloet, Marc G.
    Beishuizen, Albertus
    Groeneveld, A. B. Johan
    ASAIO JOURNAL, 2011, 57 (01) : 48 - 52
  • [36] Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration
    Lee, Bongjin
    Kim, Soo Jung
    Park, June Dong
    Park, Jiun
    Jung, Ae Hee
    Jung, Sun Hoi
    Choi, Yu Hyeon
    Kang, Hee Gyung
    Ha, Il Soo
    Cheong, Hae Il
    PLOS ONE, 2018, 13 (06):
  • [37] A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01)
    Kalaria, Shamir N.
    Armahizer, Michael
    McCarthy, Paul
    Badjatia, Neeraj
    Gobburu, Jogarao, V
    Gopalakrishnan, Mathangi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (05): : 950 - 959
  • [38] Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)
    Cheng, Vesa
    Abdul-Aziz, Mohd H.
    Burrows, Fay
    Buscher, Hergen
    Corley, Amanda
    Diehl, Arne
    Jakob, Stephan M.
    Levkovich, Bianca J.
    Pellegrino, Vincent
    Que, Yok-Ai
    Reynolds, Claire
    Rudham, Sam
    Wallis, Steven C.
    Welch, Susan A.
    Zacharias, David
    Roberts, Jason A.
    Shekar, Kiran
    Fraser, John F.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 58 (06)
  • [39] Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
    Ha Lee, Jae
    Lee, Dong-Hwan
    Kim, Jin Soo
    Jung, Won-Beom
    Heo, Woon
    Kim, Yong Kyun
    Kim, Se Hun
    No, Tae-Hoon
    Jo, Kyeong Min
    Ko, Junghae
    Lee, Ho Young
    Jun, Kyung Ran
    Choi, Hye Sook
    Jang, Ji Hoon
    Jang, Hang-Jea
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [40] Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy
    Cheng, Vesa
    Abdul-Aziz, Mohd H.
    Roberts, Jason A.
    CURRENT INFECTIOUS DISEASE REPORTS, 2021, 23 (09)